Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine

With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudousquié, Caroline, Boand, Valérie, Lingre, Emilie, Dutoit, Laeticia, Balint, Klara, Danilo, Maxime, Harari, Alexandre, Gannon, Philippe O., Kandalaft, Lana E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157441/
https://www.ncbi.nlm.nih.gov/pubmed/31947581
http://dx.doi.org/10.3390/vaccines8010025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157441/
https://www.ncbi.nlm.nih.gov/pubmed/31947581
http://dx.doi.org/10.3390/vaccines8010025

Ejemplares similares